|Bid||82.30 x 1100|
|Ask||82.57 x 800|
|Day's Range||79.74 - 82.75|
|52 Week Range||56.39 - 124.35|
|Beta (5Y Monthly)||0.79|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 28, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||94.25|
Subscribe to Yahoo Finance Plus to view Fair Value for NVCR
ROOT, Switzerland, October 03, 2022--Novocure will report financial results for the third quarter 2022 on Thursday, October 27, 2022, before the U.S. financial markets open.
As they enter the final quarter of calendar year 2022, many investors are probably wondering when the sell-off will end. This year has tested the patience of even the most experienced investors as the tech-heavy Nasdaq Composite is down over 30% from its all-time high while the S&P 500 remains down over 20%.
ROOT, Switzerland, September 21, 2022--Novocure (NASDAQ: NVCR) today announced the creation of its U.S. CNS (central nervous system) Cancers Franchise. This new organization will add resources, streamline decision-making and improve coordination across Novocure’s U.S. CNS business, and is intended to renew focus on growth in Novocure’s glioblastoma (GBM) business.